Calman A. MacLennan
BM, BCh, DPhil, FRCP, FRCPath
Professor of Vaccine Immunology (University of Birmingham)
- MRC Senior Clinical Fellow, Jenner Investigator and Group Leader - Gonococcal Vaccine Project, Jenner Institute
- Senior Program Officer - Bacterial Vaccines; Lead - Shigella Portfolio & Salmonella Vaccines Product Development, Global Health - Enteric & Diarrheal Diseases, Bill & Melinda Gates Foundation
- Director, BactiVac Bacterial Vaccinology Network; Professor of Vaccine Immunology, University of Birmingham
- Consultant Immunologist, Oxford University Hospitals NHS Trust
My main research objective is to understand the immunological basis of protection against invasive bacterial disease with a view to prevention and treatment, focusing on communities in resource-limited settings and patients with impaired immunity. My programme at the Jenner Institute aims to combine improved understanding of naturally-acquired immunity and vaccine-induced immunity to invasive bacteria, focusing on Salmonella, with a view to the development of effective and affordable vaccines against these pathogens for use in the developing world. This work involves partnership and collaboration with sites in low-income countries and exploitation of effective and affordable vaccine technologies, such as Generalized Modules for Membrane Antigens (GMMA).
Rapid transcriptional responses to serum exposure are associated with sensitivity and resistance to antibody-mediated complement killing in invasive Salmonella Typhimurium ST313
Ondari EM. et al, (2019), Wellcome Open Research, 4, 74 - 74
How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?
Giersing BK. et al, (2019), Vaccine, 37, 4778 - 4783
Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella.
Micoli F. et al, (2018), Proc Natl Acad Sci U S A, 115, 10428 - 10433